The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 201–300 of 1,008
Guo, C., Martinez-Vasquez, D., Mendez, G. P., Toniolo, M. F., Yao, T. M., Oestreicher, E. M., Kikuchi, T., Lapointe, N., Pojoga, L., Williams, G. H., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0944 · Cited by 173
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
Bilous, R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02496.x · Cited by 174
Szczech, L. A., Stewart, R. C., Su, H.-L., DeLoskey, R. J., Astor, B. C., Fox, C. H., McCullough, P. A., & Vassalotti, J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110535 · Cited by 172
“Specific to persons with T2DM, interventions focused on lowering proteinuria prolong both renal and patient survival [18, 19, 20].”
BackgroundDiabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history
Rossing, P. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0083-y · Cited by 170
Update on diagnosis, pathophysiology, and management of diabetic kidney disease
Sugahara, M., Pak, W. L. W., Tanaka, T., Tang, S. C. W., & Nangaku, M. (2021) · Nephrology · doi:10.1111/nep.13860 · Cited by 171
“IRMA-2 study demonstrated that treatment with irbesartan significantly reduced the rate of progression to overt albuminuria.(52) What”
BackgroundChoi, A. I., Li, Y., Deeks, S. G., Grunfeld, C., Volberding, P. A., & Shlipak, M. G. (2010) · Circulation · doi:10.1161/circulationaha.109.898585 · Cited by 170
Prevention of End-Stage Renal Disease Due to Type 2 Diabetes
Hostetter, T. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451209 · Cited by 169
De Nicola, L., Gabbai, F. B., Liberti, M. E., Sagliocca, A., Conte, G., & Minutolo, R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.02.010 · Cited by 167
de Zeeuw, D., Anzalone, D. A., Cain, V. A., Cressman, M. D., Heerspink, H. J. L., Molitoris, B. A., Monyak, J. T., Parving, H.-H., Remuzzi, G., Sowers, J. R., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70246-3 · Cited by 167
Self-citationKurata, A., Nishizawa, H., Kihara, S., Maeda, N., Sonoda, M., Okada, T., Ohashi, K., Hibuse, T., Fujita, K., Yasui, A., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001810 · Cited by 166
Diabetes mellitus and hypertension: key risk factors for kidney disease.
Lea, J. P., & Nicholas, S. B. (2002) · PubMed · Cited by 204
Mori, H., Inoki, K., Masutani, K., Wakabayashi, Y., Komai, K., Nakagawa, R., Guan, K.-L., & Yoshimura, A. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.136 · Cited by 165
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection
Werner, C., Baumhäkel, M., Teo, K. K., Schmieder, R., Mann, J., Unger, T., Yusuf, S., & Böhm, M. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0668-3 · Cited by 166
Detection and evaluation of chronic kidney disease.
Snyder, S. R., & Pendergraph, B. M. (2005) · PubMed · Cited by 228
Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans
Fisher, N. D. L., Jan Danser, A. H., Nussberger, J., Dole, W. P., & Hollenberg, N. K. (2008) · Circulation · doi:10.1161/circulationaha.108.767202 · Cited by 163
Renin‐Angiotensin‐Aldosterone System in Diabetes and Hypertension
Hsueh, W. A., & Wyne, K. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00449.x · Cited by 160
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-5938 · Cited by 163
The effect of RAAS blockade on the progression of diabetic nephropathy
Roscioni, S. S., Heerspink, H. J. L., & de Zeeuw, D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.251 · Cited by 162
Dhaun, N., MacIntyre, I. M., Kerr, D., Melville, V., Johnston, N. R., Haughie, S., Goddard, J., & Webb, D. J. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.167486 · Cited by 160
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study
Bakris, G. L., Toto, R. D., McCullough, P. A., Rocha, R., Purkayastha, D., & Davis, P. (2008) · Kidney International · doi:10.1038/ki.2008.102 · Cited by 158
Mancia, G., Brown, M., Castaigne, A., de Leeuw, P., Palmer, C. R., Rosenthal, T., Wagener, G., & Ruilope, L. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000057420.27692.ad · Cited by 157
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Randomized Controlled Trials of Blood Pressure Lowering in Hypertension: A Critical Reappraisal
Zanchetti, A., Thomopoulos, C., & Parati, G. (2015) · Circulation Research · doi:10.1161/circresaha.116.303641 · Cited by 155
Fink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00008 · Cited by 154
Caramori, M. L., & Mauer, M. S. (2003) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200305000-00008 · Cited by 169
Persson, F., Rossing, P. R., Reinhard, H., Juhl, T. R., Stehouwer, C. D. A., Schalkwijk, C. G., Danser, A. H. J., Boomsma, F., Frandsen, E. L., & Parving, H. (2009) · Diabetes Care · doi:10.2337/dc09-0168 · Cited by 151
Self-citationReview: Angiotensin II type 1 receptor blockers: class effects versus molecular effects
Miura, S.-I., Karnik, S. S., & Saku, K. (2010) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310370852 · Cited by 154
NHG-Standaard Diabetes mellitus type 2
Rutten, G. E. H. M., De Grauw, W. J. C., Nijpels, G., Goudswaard, A. N., Uitewaal, P. J. M., Van der Does, F. E. E., Heine, R. J., Van Ballegooie, E., Verduijn, M. M., & Bouma, M. (2009) · NHG-Standaarden voor de huisarts 2009 · doi:10.1007/978-90-313-6614-9_8 · Cited by 150
Mogensen, C. E., Viberti, G., Halimi, S., Ritz, E., Ruilope, L., Jermendy, G., Widimsky, J., Sareli, P., Taton, J., Rull, J., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000064943.51878.58 · Cited by 151
Parmar, M. S. (2002) · BMJ · doi:10.1136/bmj.325.7355.85 · Cited by 147
Backer, G. D., Ambrosio, G., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · PubMed · doi:10.1097/01.hjr.0000087913.96265.e2 · Cited by 149
Microalbuminuria in Type 2 Diabetes and Hypertension
Basi, S., Fesler, P., Mimran, A., & Lewis, J. B. (2008) · Diabetes Care · doi:10.2337/dc08-s249 · Cited by 188
Transforming Growth Factor-Beta1 in Diabetic Kidney Disease
Zhao, L., Zou, Y., & Liu, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00187 · Cited by 160
Denver, E. A., Barnard, M., Woolfson, R. G., & Earle, K. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2256 · Cited by 144
Proteinuria and its relation to cardiovascular disease
Delles, C., & Currie, G. E. (2013) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40522 · Cited by 164
South African hypertension guideline 2006.
Seedat, Y. K., Ma, C., Milne, F. J., Opie, L. H., Vj, P.-A., Rayner, B. L., & Veriava, Y. (2006) · PubMed · Cited by 162
Zelmanovitz, T., Gerchman, F., Balthazar, A. P., Thomazelli, F. C. S., de Matos, J. D., & Canani, L. H. S. (2009) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-1-10 · Cited by 184
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedMicroalbuminuria in HIV infection
Szczech, L. A. M., Grünfeld, C., Scherzer, R., Canchola, J. A., van der Horst, C., Sidney, S., Wohl, D. A., & Shlipak, M. G. (2007) · AIDS · doi:10.1097/qad.0b013e3280d3587f · Cited by 143
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns
Rossing, K., Mischak, H., Parving, H., Christensen, P. K., Walden, M., Hillmann, M., & Kaiser, T. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00394.x · Cited by 136
Self-citationThe kidney, a cardiovascular risk marker, and a new target for therapy
de Zeeuw, D., Hillege, H. L., & de Jong, P. E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09805.x · Cited by 158
The Renin-Angiotensin System and Diabetic Nephropathy
Gurley, S. B., & Coffman, T. M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.009 · Cited by 144
The Vasculature in Prediabetes
Wasserman, D. H., Wang, T. J., & Brown, N. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.311912 · Cited by 137
Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?
de Cavanagh, E. M. V., Inserra, F., & Ferder, L. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq285 · Cited by 137
Ibsen, H., Wachtell, K., Olsen, M. H., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahl??f, B., Devereux, R. B., de Faire, U., Fyhrquist, F., et al. (2004) · Journal of Hypertension · doi:10.1097/00004872-200409000-00026 · Cited by 137
Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Sharma, A. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000132568.71409.a2 · Cited by 136
miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy
Jia, Y., Guan, M., Zheng, Z., Zhang, Q., Tang, C., Xu, W.-W., Xiao, Z., Wang, L., & Xue, Y. (2016) · Journal of Diabetes Research · doi:10.1155/2016/7932765 · Cited by 145
“miRNAs in Urine Extracellular Vesicles as Predictors of”
Five preventable causes of kidney graft loss in the 1990s: A single-center analysis1
Matas, A. J., Humar, A., Gillingham, K. J., Payne, W. D., Gruessner, R. W. G., Kandaswamy, R., Dunn, D. L., Najarian, J. S., & Sutherland, D. E. R. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00491.x · Cited by 135
Renoprotective effects of vitamin D analogs
Li, Y. C. (2009) · Kidney International · doi:10.1038/ki.2009.175 · Cited by 151
Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients
Savoia, C., Touyz, R. M., Volpe, M., & Schiffrin, E. L. (2007) · Hypertension · doi:10.1161/01.hyp.0000253968.95136.b8 · Cited by 134
McMurray, J., Östergren, J., Pfeffer, M., Swedberg, K., Granger, C., Yusuf, S., Held, P., Michelson, E., & Olofsson, B. (2003) · European Journal of Heart Failure · doi:10.1016/s1388-9842(03)00052-7 · Cited by 133
Persson, F., Rossing, P. R., Schjoedt, K. J., Juhl, T. R., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C., Boomsma, F., Frandsen, E., & Parving, H.-H. (2008) · Kidney International · doi:10.1038/ki.2008.68 · Cited by 143
Self-citationZanchetti, A., & Ruilope, L. M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00001 · Cited by 135
Rosen, A. B., Hamel, M. B., Weinstein, M. C., Cutler, D. M., Fendrick, A. M., & Vijan, S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-2-200507190-00007 · Cited by 131
Srivastava, M., Tiwari, P., Srivastava, S., Prakash, R., & Ji, G. (2017) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2017.04.017 · Cited by 130
Lip, G. Y. H., Barnett, A. H., Bradbury, A. W., Cappuccio, F. P., Gill, P. S., Hughes, E. A., Imray, C., Jolly, K. B., & Patel, K. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002126 · Cited by 147
First-line drugs for hypertension
Wright, J. M., & Musini, V. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001841.pub2 · Cited by 221
Vascular and cardiac benefits of angiotensin receptor blockers
Schiffrin, E. L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01241-x · Cited by 142
Deb, D. K., Sun, T., Wong, K. E., Zhang, Z., Ning, G., Zhang, Y., Kong, J., Shi, H., Chang, A., & Li, Y. C. (2010) · Kidney International · doi:10.1038/ki.2010.22 · Cited by 134
Nagai, Y., Yao, L., Kobori, H., Miyata, K., Ozawa, Y., Miyatake, A., Yukimura, T., Shokoji, T., Kimura, S., Kiyomoto, H., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080649 · Cited by 128
Capítulo 1 - Conceituação, Epidemiologia e Prevenção Primária
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160151 · Cited by 229
Konta, T., Hao, Z., Abiko, H., Ishikawa, M., Takahashi, T., Ikeda, A., Ichikawa, K., Takasaki, S., & Kubota, I. (2006) · Kidney International · doi:10.1038/sj.ki.5001504 · Cited by 128
Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure
Tryggvason, K., & Pettersson, E. E. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01207.x · Cited by 149
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy
Julius, S., Alderman, M. H., Beevers, G., Dahlöf, B., Devereux, R. B., Douglas, J. G., Edelman, J. M., Harris, K. E., Kjeldsen, S. E., Nesbitt, S. D., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.029 · Cited by 132
Bakris, G. L. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0713 · Cited by 145
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655761 · Cited by 158
A critical review of mathematical models and data used in diabetology
Boutayeb, A., & Chetouani, A. (2006) · BioMedical Engineering OnLine · doi:10.1186/1475-925x-5-43 · Cited by 126
Ochodnicky, P., Henning, R. H., van Dokkum, R. P. E., & de Zeeuw, D. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200606001-00009 · Cited by 126
Balamuthusamy, S., Srinivasan, L., Verma, M., Adigopula, S., Jalandara, N., Hathiwala, S. C., & Smith, E. L., III (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.01.031 · Cited by 136
Nishiyama, A., Konishi, Y., Ohashi, N., Morikawa, T., Urushihara, M., Maeda, I., Hamada, M., Kishida, M., Hitomi, H., Shirahashi, N., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq371 · Cited by 132
Vijan, S. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201503030 · Cited by 125
the Italian Diabetes Society and the Italian Society of Nephrology, Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2020) · Journal of Nephrology · doi:10.1007/s40620-019-00650-x · Cited by 125
The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus
Snow, V., Weiss, K. B., Mottur-Pilson, C., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00017 · Cited by 126
Jennings, D. L., Kalus, J. S., Coleman, C. I., Manierski, C., & Yee, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02097.x · Cited by 124
Evidence-based Practice Guideline for the Treatment of CKD
(2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0237-8 · Cited by 129
9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 137
Long-term renal consequences of hypertension for normal and diseased kidneys
BIDANI, A. K., & Griffin, K. A. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200201000-00011 · Cited by 135
Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management
El-Atat, F., McFarlane, S. I., & Sowers, J. R. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0072-y · Cited by 121
Current therapeutic interventions in the glycation pathway: evidence from clinical studies
Engelen, L., Stehouwer, C. D. A., & Schalkwijk, C. G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12058 · Cited by 122
“In addition, no treatment effects on serum AGEs were found of anti-oxidant treatment with propionyl l-carnitine, sildenafil or both in individuals with T2DM and erectile dysfunction [164].”
BackgroundInfluentialDirks, J. H., de Zeeuw, D., Agarwal, S. K., Atkins, R. C., Correa‐Rotter, R., D’Amico, G., Bennett, P. H., Nahas, M. E., Valdés, R. H., Kaseje, D. A. N., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09800.x · Cited by 144
Oellgaard, J., Gæde, P., Rossing, P. R., Persson, F., Parving, H., & Pedersen, O. B. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.023 · Cited by 124
Self-citationBurnier, M., & Zanchi, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000191244.91314.9d · Cited by 129
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus
Hollenberg, N. K., Price, D. A., Fisher, N. D. L., Lansang, M. C., Perkins, B. A., Gordon, M. S., Williams, G. H., & Laffel, L. M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00701.x · Cited by 123
Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Raimondo, D. D., Tuttolomondo, A., Buttà, C., Miceli, S., Licata, G., & Pinto, A. V. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802481282 · Cited by 135
Benefits of dietary sodium restriction in the management of chronic kidney disease
Krikken, J. A., Laverman, G. D., & Navis, G. J. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283312fc8 · Cited by 120
Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes
Joergensen, C., Hovind, P. H., Schmedes, A., Parving, H., & Rossing, P. R. (2011) · Diabetes Care · doi:10.2337/dc10-2459 · Cited by 117
Self-citationEarlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay
Comper, W. D., Osicka, T. M., Clark, M., MacIsaac, R. J., & Jerums, G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00585.x · Cited by 116
Lewis, E. J., Lewis, J. B., Greene, T., Hunsicker, L. G., Berl, T., Pohl, M. A., de Zeeuw, D., Heerspink, H. J. L., Rohde, R. D., Atkins, R. C., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.06.020 · Cited by 124
New pharmacological treatments for improving renal outcomes in diabetes
Declèves, A., & Sharma, K. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.57 · Cited by 120
Kwakernaak, A. J., Krikken, J. A., Binnenmars, S. H., Visser, F. W., Hemmelder, M. H., Woittiez, A.-J. J., Groen, H., Laverman, G. D., & Navis, G. J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70030-0 · Cited by 131
RAS inhibition in hypertension
Ibrahim, M. M. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001960 · Cited by 114
The Burden of Uncontrolled Hypertension: Morbidity and Mortality Associated With Disease Progression
Cushman, W. C. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02464.x · Cited by 134
O’Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., & Larson, E. B. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00010 · Cited by 120
Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?
Gallagher, H., & Suckling, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12630 · Cited by 119
“The benefits extend beyond blood pressure effects alone, with blood pressure-independent renoprotective properties observed in individuals with type 1 diabetes and nephropathy [44,45] and in those with type 2 diabetes and both incipient [46] and established [47,48] nephropathy.”
BackgroundMaione, A., Navaneethan, S. D., Graziano, G., Mitchell, R. L., Johnson, D. W., Mann, J. F. E., Gao, P., Craig, J. C., Tognoni, G., Perkovic, V., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq792 · Cited by 123
“After assessing the full text of 357 studies, we included 85 eligible RCTs (from 86 publications) which enrolled 21 708 patients [19, 22–62] [63–103] [104–107] 48 RCTs reported either only hard outcomes or a combination of hard and surrogate end points; the remaining 37 RCTs only reported surrogate outcomes.”
BackgroundRuggenenti, P. L., Cattaneo, D., Loriga, G., Ledda, F., Motterlini, N., Gherardi, G., Orisio, S., & Remuzzi, G. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.132522 · Cited by 126
Mourad, J., Waeber, B., Zannad, F. E., Laville, M., Duru, G., & jak, M. A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00021 · Cited by 132
Role of oxidative stress in diabetic nephropathy
Vasavada, N., & Agarwal, R. (2005) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2005.01.001 · Cited by 126
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001971 · Cited by 109
“Six drug manufacturers (Boehringer Ingelheim for ONTARGET [Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial] [40,41], PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes] [47], and TRANSCEND [Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiov…”
BackgroundWada, M., Nagasawa, H., Kurita, K., Koyama, S., Arawaka, S., Kawanami, T., Tajima, K., Daimon, M., & Kato, T. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.066 · Cited by 113
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.